"Hormonal acne" is a useful search phrase, but it can hide the real decision.
After 40, recurring jawline bumps may be acne. They may also be rosacea, folliculitis, dermatitis, a medication eruption, irritation from skin care, or acne plus androgen clues. The first job is to name the pattern.
The 2024 American Academy of Dermatology acne guideline strongly recommends benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline for appropriate acne patients. It conditionally recommends topical clascoterone, salicylic acid, azelaic acid, minocycline, sarecycline, combined oral contraceptives, and spironolactone. [1]
That hierarchy is the safest starting point. Hormonal acne treatment after 40 should not mean "skip straight to hormone manipulation." It should mean acne diagnosis, acne severity, midlife safety review, and then the treatment category that fits.
First confirm what the breakout is
Adult female acne can persist from adolescence or appear for the first time in adulthood. Adult female acne reviews describe a more complex pattern than teenage acne, with hormonal, genetic, medication, skin-care, and chronic-course factors. [3]
In practice, a clinician is usually sorting several look-alikes:
| Pattern | More likely category | Why treatment changes |
|---|---|---|
| Blackheads, whiteheads, clogged pores | Comedonal acne | Retinoid and benzoyl peroxide planning may fit. |
| Inflamed bumps or pustules | Inflammatory acne | Benzoyl peroxide, topical antibiotic pairing, oral antibiotic, or other acne care may fit. |
| Deep tender jawline nodules | Adult female acne, androgen-sensitive acne, or cystic acne | Spironolactone or dermatology review may be considered, but scarring risk matters. |
| Flushing, burning, visible vessels, heat or alcohol triggers | Rosacea overlap | Acne escalation can worsen irritation. |
| Itchy, uniform follicle-centered bumps | Folliculitis | Acne products may miss the cause. |
| Sudden severe acne plus facial hair, scalp thinning, voice change, or clitoral symptoms | Androgen-excess or medication-exposure concern | Routine acne treatment should slow down until the cause is reviewed. [4] [5] |
This is why "hormonal" is not enough. It points to a possible driver, not a diagnosis.
What "hormonal" usually means in acne care
In acne care, hormonal usually means the acne pattern may be sensitive to androgen signaling. Androgens can increase oil production and contribute to clogged pores and inflammation.
Adult female acne and androgen-excess guidance says acne can be one clinical sign of androgen excess, especially when it is sudden, severe, treatment resistant, or paired with hirsutism, scalp hair thinning, oily skin, polycystic ovary syndrome history, or virilizing symptoms. [4]
That does not mean blood tests are needed for every adult breakout. It means the visit should ask better questions:
- Did acne start suddenly or become severe after 40?
- Are there new coarse facial hairs, scalp thinning, oily skin, or body-hair changes?
- Is there a history of polycystic ovary syndrome, irregular periods, infertility, insulin resistance, or ovarian/adrenal disease?
- Has testosterone, dehydroepiandrosterone, anabolic steroid, lithium, corticosteroid, or another acne-triggering medication been started?
- Is there bleeding after 12 months without a period?
The Endocrine Society hirsutism guideline is not an acne guideline, but it gives a useful boundary: androgen testing is more relevant when hair-growth signs are abnormal or progressing, especially with menstrual irregularity or progression. [5]
The treatment ladder
The useful question is not "natural or hormonal?" It is "which acne mechanism and which risk profile?"
| Treatment category | Where it can fit | Key boundary |
|---|---|---|
| Benzoyl peroxide | Inflamed acne, antibiotic-resistance-conscious routines, mild to moderate acne | Can dry or irritate skin; may bleach fabrics. |
| Topical retinoids such as adapalene or tretinoin | Clogged pores, maintenance, acne plus texture concerns | Dry, reactive, or pigment-prone midlife skin may need slower introduction. [1] [9] |
| Azelaic acid | Acne with pigment marks, rosacea overlap, or lower-irritation goals | Often useful, but expectations should match severity. [1] |
| Topical antibiotics | Inflamed acne when paired with benzoyl peroxide | Long-term antibiotic-only routines are a poor fit. [1] |
| Oral doxycycline or related antibiotics | More inflammatory acne when topical care is not enough | Use should be time-limited and paired with topical therapy. [1] |
| Clascoterone | Topical androgen-receptor acne option | Approved by the Food and Drug Administration for acne, but still needs irritation and label-specific safety review. [7] |
| Spironolactone | Selected adult women with androgen-sensitive or persistent acne | Requires kidney, potassium, blood pressure, pregnancy potential, and interaction review. [2] [6] |
| Combined oral contraceptives | Selected premenopausal or perimenopausal patients who need contraception and meet safety criteria | National contraceptive-safety screening matters, especially after 35. [8] |
| Oral isotretinoin | Severe, scarring, psychosocially burdensome, or treatment-resistant acne | Dermatology-led risk management and pregnancy prevention requirements apply. [1] |
This ladder also explains why personalized topical plans can be useful. A clinician may adjust ingredients, strength, vehicle, and pacing when dry midlife skin cannot tolerate a standard acne routine. That personalization is a benefit when it is tied to diagnosis and follow-up; it should not be used to blur prescription boundaries or promise that a custom mixture treats every hormonal driver.
Where spironolactone fits
Spironolactone is often the medication people mean when they search for hormonal acne treatment.
The strongest recent randomized evidence is the SAFA trial. It enrolled 410 adult women with facial acne for at least 6 months, severe enough that oral antibiotics would have been reasonable. Participants used spironolactone 50 mg/day or placebo until week 6, then 100 mg/day until week 24, while continuing topical treatment if needed. [2]
The difference was more obvious at 24 weeks than 12 weeks. At week 24, 82% of spironolactone participants reported improvement versus 63% with placebo. Investigator-rated treatment success at week 12 was 19% versus 6%. Headache was more common with spironolactone, and no serious adverse reactions were reported in the trial. [2]
That supports a real treatment conversation. It does not make spironolactone automatic.
DailyMed labeling for spironolactone warns about hyperkalemia, hypotension and worsening renal function, electrolyte and metabolic abnormalities, and drug interactions with potassium-raising medicines. It also notes pregnancy concerns based on animal data. [6]
So the fit question is practical:
| Better fit | Poorer fit or needs extra caution |
|---|---|
| Adult woman with persistent jawline or lower-face acne, no urgent red flags, and acne that has not responded enough to topical care. | Kidney disease, high potassium risk, potassium supplements, certain blood-pressure medicines, low blood pressure, complex medication lists, pregnancy potential, or breastfeeding questions. |
| Acne plus mild facial hair or androgen-sensitive pattern after clinician review. | Rapid virilizing symptoms, sudden severe acne, postmenopausal bleeding, or a new hormone exposure that needs diagnosis first. |
| Patient willing to wait months and track response. | Expecting a same-week acne fix. |
Clascoterone and topical anti-androgen options
Clascoterone is a topical androgen receptor inhibitor. The label says Winlevi, clascoterone cream 1%, is indicated for topical treatment of acne vulgaris in patients 12 years and older. [7]
It can be useful to discuss when the reader wants a topical, non-antibiotic option that targets androgen signaling in the skin. It is not the same as oral spironolactone, and it is not a full endocrine workup.
The label also matters. Clascoterone can cause local irritation such as itching, burning, redness, or peeling, and the label discusses hypothalamic-pituitary-adrenal axis suppression. [7]
The practical position is narrow: clascoterone may fit selected acne patients as part of a clinician-directed plan. It should not be marketed as "hormone balancing" skin care.
Oral contraceptives after 40 need a separate safety screen
Combined oral contraceptives are conditionally recommended in acne guidelines for appropriate patients. [1] They can be helpful when contraception is also desired and safety criteria fit.
After 35 and 40, that safety screen becomes more important. The 2024 U.S. Medical Eligibility Criteria from the Centers for Disease Control and Prevention classifies combined hormonal contraceptive use by factors such as smoking, blood pressure, migraine, vascular disease, clot risk, postpartum status, cardiovascular risk factors, and other medical conditions. [8]
For a midlife acne article, that means oral contraceptives should not be presented as a casual acne add-on. They may fit some perimenopausal patients. They are usually irrelevant after menopause and unsafe or inappropriate for others.
Red flags before treating it like routine hormonal acne
Get clinician review before routine acne treatment if any of these are present:
| Red flag | Why it matters |
|---|---|
| Sudden severe acne after 40 | May need dermatology or endocrine review before routine prescriptions. |
| Painful nodules, scarring, or rapidly worsening cysts | Early dermatology care can reduce scarring risk. |
| Rapidly increasing facial hair, scalp thinning, voice deepening, clitoral symptoms, or fast muscle changes | These can be androgen-excess or hormone-exposure clues. [4] [5] |
| Bleeding after 12 months without a period | This needs evaluation separate from acne care. |
| Fever, spreading redness, warmth, pus, or severe tenderness | Infection or another inflammatory condition may need different care. |
| Changing pigmented lesion, bleeding spot, or nonhealing sore | Do not cover a lesion that first needs diagnosis. |
| Acne started after testosterone, dehydroepiandrosterone, anabolic steroids, lithium, corticosteroids, or a new supplement | The trigger may be the exposure, not a skin-care failure. |
Red flags do not mean acne treatment is impossible. They mean diagnosis and safety come first.
What to ask your clinician
Ask questions that force the plan to be specific:
- Is this acne, rosacea, folliculitis, dermatitis, medication eruption, or a lesion that needs examination?
- Is my acne comedonal, inflammatory, nodular, scarring, pigment-prone, or rosacea-overlap?
- Do facial hair, scalp thinning, oily skin, cycle changes, polycystic ovary syndrome history, testosterone, dehydroepiandrosterone, steroid exposure, or postmenopausal bleeding change the workup?
- Which baseline topical plan fits my skin: benzoyl peroxide, retinoid, azelaic acid, clascoterone, or a combination?
- If topical antibiotics are used, what benzoyl peroxide pairing and stop date reduce resistance risk?
- If spironolactone is considered, how will kidney function, potassium risk, blood pressure, pregnancy potential, and current medicines be reviewed?
- If combined oral contraceptives are considered, do national contraceptive-safety criteria make them a safe fit for me?
- What result should we expect by 8 to 12 weeks, and what result should we expect later if using spironolactone?
Bottom line
Hormonal acne treatment after 40 should be diagnosis-first and safety-first.
A strong plan confirms acne, rules out common mimics, checks androgen and medication clues, protects dry or pigment-prone skin, and then chooses from guideline-supported options. Spironolactone can help selected adult women, clascoterone may fit as a topical androgen-receptor option, and standard acne treatments still matter.
The goal is not to chase hormones. The goal is to match the acne pattern to a treatment that is strong enough, tolerable enough, and safe enough for the body being treated.
Related reading:
- Acne After Menopause.
- Perimenopause Acne.
- Azelaic Acid After Menopause.
- Topical Clindamycin Over the Counter?.
- Prescription Skin Care After Menopause.
References
[1] Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-1006.e30. doi:10.1016/j.jaad.2023.12.017 https://pubmed.ncbi.nlm.nih.gov/38300170/
[2] Santer M, Lawrence M, Renz S, et al. Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. BMJ. 2023;381:e074349. doi:10.1136/bmj-2022-074349 https://pubmed.ncbi.nlm.nih.gov/37192767/
[3] Bagatin E, Freitas THP, Rivitti-Machado MC, et al. Adult female acne: a guide to clinical practice. An Bras Dermatol. 2019;94(1):62-75. doi:10.1590/abd1806-4841.20198203 https://pubmed.ncbi.nlm.nih.gov/30726466/
[4] Carmina E, Dreno B, Lucky WA, et al. Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. J Endocr Soc. 2022;6(3):bvac003. doi:10.1210/jendso/bvac003 https://pubmed.ncbi.nlm.nih.gov/35155970/
[5] Martin KA, Anderson RR, Chang RJ, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(4):1233-1257. doi:10.1210/jc.2018-00241 https://pubmed.ncbi.nlm.nih.gov/29522147/
[6] DailyMed. Spironolactone tablet, coated prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08738ad4-1607-4d55-af71-6790477353bd
[7] DailyMed. WINLEVI (clascoterone) cream prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1673a84b-7f5c-47ab-a99c-1e3db21a6a09
[8] Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. https://www.cdc.gov/mmwr/volumes/73/rr/rr7304a1.htm
[9] DailyMed. RETIN-A (tretinoin) cream and gel prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9556d73d-c573-4e0a-9feb-764ce2d1107b